Managing Dronedarone in obese AF patients effectively is crucial as the dual burden of atrial fibrillation (AF) and high body mass index (BMI) continues to rise globally. Obesity is a major risk factor for AF recurrence and cardiovascular complications. Consequently, clinicians often seek clarity on whether antiarrhythmic drugs maintain their performance in patients with higher body fat. A recent post-hoc analysis of the landmark ATHENA trial provides robust evidence regarding the efficacy and safety of dronedarone across various weight categories.

Impact of BMI on Cardiovascular Outcomes

Researchers analyzed data from over 4,600 patients to determine if BMI influenced the drug's therapeutic impact. They categorized participants into normal weight, overweight, and obese groups. The study found that patients with a higher BMI generally faced an increased baseline risk of cardiovascular events. However, the relative benefit of dronedarone remained remarkably consistent regardless of the patient's weight. Dronedarone successfully reduced the primary composite endpoint of cardiovascular hospitalization or death from any cause in all three groups.

Efficacy of Dronedarone in Obese AF Patients

Specifically, the analysis showed that Dronedarone in obese AF patients significantly lowered the risk of first cardiovascular hospitalization. This finding is particularly important because obesity often complicates rhythm control strategies. Furthermore, the risk reduction for AF-related hospitalizations was similar across the BMI spectrum. This suggests that the pharmacological action of dronedarone is not diminished by the physiological changes associated with excess body weight. Therefore, clinicians can consider dronedarone a reliable option for rhythm management in this challenging population.

Safety and Tolerability Profiles

Safety is a paramount concern when treating patients with multiple comorbidities. The analysis revealed that serious treatment-emergent adverse events did not increase with rising BMI. While gastrointestinal side effects led to some discontinuations, these occurred at similar rates across weight classes. Importantly, no interaction effect between BMI and the drug’s safety profile was observed. Consequently, the manageable safety profile of dronedarone makes it a viable long-term treatment even for patients with severe obesity.

FAQs

Does Dronedarone require dose adjustments for obese patients?

Currently, the standard dose of 400 mg twice daily is used regardless of BMI. The ATHENA analysis did not suggest a need for weight-based titration for efficacy or safety.

Is Dronedarone more effective in normal-weight patients?

While normal-weight patients showed a significant reduction in all-cause mortality in this analysis, the reduction in cardiovascular hospitalizations was consistent and significant across all weight categories, including those with obesity.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always consult a qualified healthcare provider for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Vamos M et al. Efficacy and Safety of Dronedar one in Overweight and Obesity: Post Hoc Analysis of the ATHENA Trial. J Cardiovasc Electrophysiol. 2026 Mar 22. doi: 10.1111/jce.70322. PMID: 41865291.

2. Hohnloser SH, et al. Effect of dronedarone on cardiovascular outcomes in atrial fibrillation. N Engl J Med. 2009 Feb 12;360(7):668-78.

3. Hindricks G, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. Eur Heart J. 2021 Feb 1;42(5):373-498.